Physician profile
Benjamin Reiss
NPI 1659637668
$1,556.43
in general payments reported to CMS, 2019-2025
15 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $85.72 · 2021: $67.29 · 2022: $320 · 2023: $134 · 2024: $399 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.58 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $284.21 | 2019-2024 | Vabysmo |
| Alimera Sciences, INC. | $234.18 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $232.42 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $200.09 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $111.61 | 2024 | Constellation, Clareon |
| Allergan, INC. | $104.34 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $93.92 | 2022-2024 | Syfovre |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $51.49 | 2023 | |
| Notal Vision, INC. | $47.78 | 2021 | |
| Genentech, INC. | $41.68 | 2024 | Vabysmo |
| Ani Pharmaceuticals, INC. | $24.88 | 2025 | Iluvien |
| Biogen, INC. | $22.51 | 2024 | Byooviz |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Enterprises LLC | $18.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Reiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.